These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nabilone could treat chorea and irritability in Huntington's disease. Curtis A; Rickards H J Neuropsychiatry Clin Neurosci; 2006; 18(4):553-4. PubMed ID: 17135385 [No Abstract] [Full Text] [Related]
3. [Patients at the memory clinic with choreatic movements]. Klompe LA; Eerenberg JG; Verschoor CJ Tijdschr Gerontol Geriatr; 2011 Feb; 42(1):29-33. PubMed ID: 21400960 [TBL] [Abstract][Full Text] [Related]
4. [Choreatic syndrome at 79 years old: late manifestation of Huntington's chorea]. Vachalova I; Golden V; Großkopf J; Heckmann JG Nervenarzt; 2013 Dec; 84(12):1502-3. PubMed ID: 24264646 [No Abstract] [Full Text] [Related]
5. Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report. Chari S; Quraishi SH; Jainer AK Pharmacopsychiatry; 2003 Jan; 36(1):41-3. PubMed ID: 12649776 [No Abstract] [Full Text] [Related]
6. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Curtis A; Mitchell I; Patel S; Ives N; Rickards H Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035 [TBL] [Abstract][Full Text] [Related]
8. Assessment of coenzyme Q10 tolerability in Huntington's disease. Feigin A; Kieburtz K; Como P; Hickey C; Claude K; Abwender D; Zimmerman C; Steinberg K; Shoulson I Mov Disord; 1996 May; 11(3):321-3. PubMed ID: 8723151 [TBL] [Abstract][Full Text] [Related]
9. High-dose olanzapine in Huntington's disease. Bonelli RM; Niederwieser G; Tribl GG; Költringer P Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191 [TBL] [Abstract][Full Text] [Related]
10. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea. Walters AS; McHale D; Sage JI; Hening WA; Bergen M Clin Neuropharmacol; 1990 Jun; 13(3):236-40. PubMed ID: 2141544 [TBL] [Abstract][Full Text] [Related]
11. A controlled trial of remacemide hydrochloride in Huntington's disease. Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144 [TBL] [Abstract][Full Text] [Related]
12. Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures. Reilmann R; Bohlen S; Kirsten F; Ringelstein EB; Lange HW Mov Disord; 2011 Oct; 26(12):2267-73. PubMed ID: 21661053 [TBL] [Abstract][Full Text] [Related]